HPC
SGTX

HM Payson & Co’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

HM Payson & Co’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-79
Closed -$23K – 1198
2021
Q1 		$23K Hold
79
– – ﹤0.01% 729
2020
Q4 		$49K Buy
+79
New +$35.8K ﹤0.01% 611

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HM Payson & Co's SGTX Position: Q2 2021 in Review

HM Payson & Co sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2021, closing a stake of 79 shares — an estimated $23K sold.

HM Payson & Co first reported a position in SGTX in Q4 2020 and held it in 2 quarters. The position peaked at $49K in Q4 2020. 52 funds tracked by Wall St. Rank hold SGTX as of Q2 2021.

  • HM Payson & Co reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 79 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $23K.
  • HM Payson & Co first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • HM Payson & Co's Sigilon Therapeutics, Inc. Common Stock position peaked at $49K in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.